
    
      Human immunodeficiency virus type 1(HIV-1) infected patients who have had an undetectable
      viral load on an enfuvirtide containing regimen at the Kaiser Permanente Hayward, Los
      Angeles, San Francisco, and Santa Clara Medical Centers will be enrolled. Patients will
      receive open label MK-0518 (raltegravir) 400mg orally twice a day as substitution for
      enfuvirtide for 24 weeks.
    
  